Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a research trial that seeks to break up the total radiation dose into multiple smaller radiation treatments, termed fractionated stereotactic radiosurgery (FSRS) which may make the treatment feasible. Fractionated sterotatcic radiation, the risks of FSRS, and possible costs will be described later in this document. This clinical trial is for people who have had no prior whole brain radiation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fractionated Stereotactic Radiosurgery | Other | 24 to 36 Gy in 3 fractions (8-12 Gy/fx). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fractionated Stereotactic Radiosurgery | Radiation | SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients Experiencing DLT | The number of patients experiencing DLT, defined as the maximum amount of Gy fractionated stereotactic radiosurgery (FSRS) delivered without significant toxicity. | Up to 3 years |
| Maximum Tolerated Dose (MTD) | The MTD was determined following a Time-to-Event Continual Reassessment Model which models toxicity as a function of dose. Treatment was given in 3 fractions (8-12 Gy/fx). | Up to 24 months post completion of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Best Response | Percentage of patients with Complete Response (CR), Partial Response (PR), or Stable Disease (SD) in the target lesion, or Progressive Disease (PD) per RECIST v1.1. (CR): the disappearance of a target lesion. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. (PR): at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. (PD): at least a 20% increase in the sum of diameters of target lesions, taking as a reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (the appearance of one or more new lesions is also considered progression). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steve Burton, MD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UPMC Shadyside Radiation Oncology | Pittsburgh | Pennsylvania | 15232 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Fractionated Stereotactic Radiosurgery - 24Gy | 24 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| FG001 | Fractionated Stereotactic Radiosurgery - 27Gy | 27 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| FG002 | Fractionated Stereotactic Radiosurgery - 30 Gy | 30 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| FG003 | Fractionated Stereotactic Radiosurgery - 33 Gy | 33 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| FG004 | Fractionated Stereotactic Radiosurgery - 36 Gy | 36 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Fractionated Stereotactic Radiosurgery - 24 Gy | 24 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| BG001 | Fractionated Stereotactic Radiosurgery - 27 Gy |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Patients Experiencing DLT | The number of patients experiencing DLT, defined as the maximum amount of Gy fractionated stereotactic radiosurgery (FSRS) delivered without significant toxicity. | All treated patients. | Posted | Number | participants | Up to 3 years |
|
Adverse Events data collected for a total of 10 years for the study population. Up to approximately 24 months after start of treatment for individuals.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Fractionated Stereotactic Radiosurgery - 24 Gy | 24 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Febrile neutropenia | Blood and lymphatic system disorders | CTCAE (4.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Febrile neutropenia | Blood and lymphatic system disorders | CTCAE (4.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Barbara Stadterman, MPH, MSCCR, CCRP, Clinical Research Manager | UPMC Hillman Cancer Center | 4126475554 | stadtermanbm@upmc.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 15, 2022 | Apr 3, 2025 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D016634 | Radiosurgery |
| ID | Term |
|---|---|
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
| D013238 | Stereotaxic Techniques |
| D019635 | Neurosurgical Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to 24 months after completion of treatment |
| Local Control of Disease | Percentage of patients with local control, defined as stable disease (SD), partial response (PR), or complete response (CR) in the target lesion, per RECIST v1.1. Complete Response (CR): the disappearance of a target lesion. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm., Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. | Up to 24 months after completion of treatment |
| Regional Intracranial Failure | Percentage of patients who develop new lesions outside the target volume. Patients without follow-up scans are excluded as it is not known if they developed lesions outside the target volume. | Up to 24 months after completion of treatment |
| Functional Assessment of Cancer Therapy - Brain (FACT-Br) | Functional Assessment of Cancer Therapy - Brain (FACT-Br) is a 50 item, self-administered questionnaire used to assess Quality of Life, including, Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. Subscale scores range from 0-4. FACT-G = (PWB - 7 items, score range 0-28) + (SWB - 7 items, score range 0-28) + (EWB - 6 items, score 0-24) + (FWB - 7 items, 0-28). The assessment takes 10-15 minutes to completed and is scored using a 5-point Likert-type scale. Scores range from 0-108, with higher scores indicating better Quality of Life. | Prior to treatment; 30 days post treatment; 8 -12 weeks, 22-28 weeks, 30-42 weeks, 45-60 weeks, 64-74 weeks, 80-84 weeks, 90-96 weeks,100-112 weeks, 120-124 weeks, 130-140 weeks, 145-155 weeks, and 160-170 weeks post treatment |
27 Gy in 3 fractions (8-12 Gy/fx).
Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
| BG002 | Fractionated Stereotactic Radiosurgery - 30 Gy | 30 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| BG003 | Fractionated Stereotactic Radiosurgery - 33 Gy | 33 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| BG004 | Fractionated Stereotactic Radiosurgery - 36 Gy | 36 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| BG005 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| OG002 | Fractionated Stereotactic Radiosurgery - 30 Gy | 30 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| OG003 | Fractionated Stereotactic Radiosurgery - 33 Gy | 33 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
| OG004 | Fractionated Stereotactic Radiosurgery - 36 Gy | 36 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery |
|
|
| Primary | Maximum Tolerated Dose (MTD) | The MTD was determined following a Time-to-Event Continual Reassessment Model which models toxicity as a function of dose. Treatment was given in 3 fractions (8-12 Gy/fx). | All treated patients evaluable for DLTs | Posted | Number | Gy | Up to 24 months post completion of treatment |
|
|
|
| Secondary | Best Response | Percentage of patients with Complete Response (CR), Partial Response (PR), or Stable Disease (SD) in the target lesion, or Progressive Disease (PD) per RECIST v1.1. (CR): the disappearance of a target lesion. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. (PR): at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. (PD): at least a 20% increase in the sum of diameters of target lesions, taking as a reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (the appearance of one or more new lesions is also considered progression). | Treated patients who were radiologically evaluable. | Posted | Count of Participants | Participants | Up to 24 months after completion of treatment |
|
|
|
| Secondary | Local Control of Disease | Percentage of patients with local control, defined as stable disease (SD), partial response (PR), or complete response (CR) in the target lesion, per RECIST v1.1. Complete Response (CR): the disappearance of a target lesion. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm., Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. | Treated patients who were radiologically evaluable. | Posted | Number | percentage of participants | Up to 24 months after completion of treatment |
|
|
|
| Secondary | Regional Intracranial Failure | Percentage of patients who develop new lesions outside the target volume. Patients without follow-up scans are excluded as it is not known if they developed lesions outside the target volume. | Treated patients who were radiologically evaluable. | Posted | Number | percentage of patients | Up to 24 months after completion of treatment |
|
|
|
| Secondary | Functional Assessment of Cancer Therapy - Brain (FACT-Br) | Functional Assessment of Cancer Therapy - Brain (FACT-Br) is a 50 item, self-administered questionnaire used to assess Quality of Life, including, Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. Subscale scores range from 0-4. FACT-G = (PWB - 7 items, score range 0-28) + (SWB - 7 items, score range 0-28) + (EWB - 6 items, score 0-24) + (FWB - 7 items, 0-28). The assessment takes 10-15 minutes to completed and is scored using a 5-point Likert-type scale. Scores range from 0-108, with higher scores indicating better Quality of Life. | All participants who provided self-administered QoL surveys. | Posted | Mean | Standard Deviation | score on a scale | Prior to treatment; 30 days post treatment; 8 -12 weeks, 22-28 weeks, 30-42 weeks, 45-60 weeks, 64-74 weeks, 80-84 weeks, 90-96 weeks,100-112 weeks, 120-124 weeks, 130-140 weeks, 145-155 weeks, and 160-170 weeks post treatment |
|
|
|
| 4 |
| 4 |
| 1 |
| 4 |
| 3 |
| 4 |
| EG001 | Fractionated Stereotactic Radiosurgery - 27 Gy | 27 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery | 1 | 2 | 0 | 3 | 2 | 2 |
| EG002 | Fractionated Stereotactic Radiosurgery - 30 Gy | 30 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery | 3 | 3 | 0 | 2 | 3 | 3 |
| EG003 | Fractionated Stereotactic Radiosurgery - 33 Gy | 33 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery | 2 | 2 | 0 | 3 | 2 | 2 |
| EG004 | Fractionated Stereotactic Radiosurgery - 36 Gy | 36 Gy in 3 fractions (8-12 Gy/fx). Fractionated Stereotactic Radiosurgery: SRS SBRT CyberKnife Trilogy True Beam Radiosurgery | 8 | 9 | 0 | 9 | 9 | 9 |
| Anemia | Blood and lymphatic system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Sinus tachycardia | Cardiac disorders | CTCAE (4.0) | Systematic Assessment |
|
| Vestibular disorder | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Tinnitus | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hearing impaired | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Ear pain | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Cushingoid | Endocrine disorders | CTCAE (4.0) | Systematic Assessment |
|
| Blurred vision | Eye disorders | CTCAE (4.0) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Mucositis oral | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Pain | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Non-cardiac chest pain | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Localized edema | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hypothermia | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| General disorders and administration site conditions - Other, specifythrush | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| General disorders and administration site conditions - Other, specifylymphadenopathy | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Gait disturbance | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Fever | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Fatigue | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Edema limbs | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Chills | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| Skin infection | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| Sepsis | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| Papulopustular rash | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| Lung infection | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| Infections and infestations - Other, specifyThrush | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| Bruising | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| Weight gain | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Platelet count decreased | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Neutrophil count decreased | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Lymphocyte count decreased | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Hyponatremia | Metabolism and nutrition disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hypernatremia | Metabolism and nutrition disorders | CTCAE (4.0) | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | CTCAE (4.0) | Systematic Assessment |
|
| Musculoskeletal and connective tissue disorder - Other, specifyrhabdomyolysis | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Musculoskeletal and connective tissue disorder - Other, specifyBursitis | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Muscle weakness lower limb | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Generalized muscle weakness | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Flank pain | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Bone pain | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Tremor | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Somnolence | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Seizure | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Paresthesia | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Nystagmus | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Nervous system disorders - Other, specifyPositive Romberg Sign | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Memory impairment | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Headache | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Dysphasia | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Cognitive disturbance | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Ataxia | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Depression | Psychiatric disorders | CTCAE (4.0) | Systematic Assessment |
|
| Urinary tract obstruction | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Urinary incontinence | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Renal and urinary disorders - Other, specifyNocturia | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Gynecomastia | Reproductive system and breast disorders | CTCAE (4.0) | Systematic Assessment |
|
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Pleuritic pain | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hoarseness | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Rash maculo-papular | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Rash acneiform | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Dry skin | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Thromboembolic event | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
| Superior vena cava syndrome | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hypotension | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D013514 |
| Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
| Partial Response |
|
| Stable Disease |
|
| Progressive Disease |
|
| Local Control - No |
|
| Unknown - no FU scans |
|
| No |
|
|
| 30 days post treatment |
|
|
| 8-16 weeks post treatment |
|
|
| 22-28 weeks post treatment |
|
|
| 30-42 weeks post treatment |
|
|
| 45-60 weeks post treatment |
|
|
| 64-74 weeks post treatment |
|
|
| 80-84 weeks post treatment |
|
|
| 90-96 weeks post treatment |
|
|
| 100-112 weeks post treatment |
|
|
| 120-124 weeks post treatment |
|
|
| 130-140 weeks post treatment |
|
|
| 145-155 weeks post treatment |
|
|
| 160-170 weeks post treatment |
|
|